Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab
By linking disease activity measures with PROs, we identified four distinct trajectories describing SLE evolution following the initiation of therapy. This classification could be valuable for personalizing treatment and guiding biological studies aimed at distinguishing patients with varying anticipated treatment responses, as no single clinical variable alone can predict disease progression.
Authors
- Julius Lindblom
- Leonardo Palazzo (ORCID: https://orcid.org/0000-0002-2652-7447)
- Yvonne Enman (ORCID: https://orcid.org/0000-0002-9600-9995)
- Dionysis Nikolopoulos (ORCID: https://orcid.org/0000-0002-9894-6966)
- Alexander Tsoi (ORCID: https://orcid.org/0009-0004-4815-7477)
- Lorenzo Beretta (ORCID: https://orcid.org/0000-0002-6529-6258)
- Ioannis Parodis (ORCID: https://orcid.org/0000-0002-4875-5395)
- Karin Blomkvist Sporre
Institutions
- Karolinska University Hospital (SE)
- Örebro University (SE)
- Swedish Rheumatism Association (SE)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1093/rheumatology/keae575
- Citations
- 4
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- GlaxoSmithKline
- Karolinska Institutet
- Svenska Läkaresällskapet
- Stiftelsen Konung Gustaf V:s 80-årsfond
- Reumatikerförbundet
- Ulla och Gustaf af Ugglas Stiftelse